About the Results of Vaccination against COVID-19 for Employees of a Cheboksary Medical Organization

N. Nikolaev, V. V. Nazarova, N. N. Pchelova, E. Preobrazhenskaya, T. Tarasova, N. Y. Dobrovol’skaya
{"title":"About the Results of Vaccination against COVID-19 for Employees of a Cheboksary Medical Organization","authors":"N. Nikolaev, V. V. Nazarova, N. N. Pchelova, E. Preobrazhenskaya, T. Tarasova, N. Y. Dobrovol’skaya","doi":"10.31631/2073-3046-2023-22-2-86-94","DOIUrl":null,"url":null,"abstract":"Relevance. In the 21st century, humanity is faced with a pandemic unprecedented in recent history, which brought with it huge losses. All the efforts of world science are aimed at ensuring that the new coronavirus infection becomes vaccine-controlled. The Ministry of Health of Russia included vaccination against COVID-19 in the national calendar of preventive vaccinations. The most vulnerable and significant in the epidemiological chain are representatives of socially active, intensively communicating professions, including medical workers.Aims. The aim of the study was to assess the degree of severity of the post-vaccination immune response in employees of a medical organization vaccinated with the Gam-COVID-Vac preparation, who had not been ill and did not have antibodies before vaccination.Materials & Methods. The post-vaccination immunity of 80 vaccinated employees was assessed 42–62 days after the start of vaccination and 6 months later; assessment of the safety of vaccination with the Gam-Kovid-Vak vector vaccine; selection of optimal screening tests for laboratory examination of persons before the planned vaccination. The results of the PCR test for the detection of SARS-CoV-2 RNA (at the post-vaccination stage four times with an interval of 7 days) and the determination of M and G immunoglobulins to SARS-CoV-2 by the ELISA method were analyzed, postvaccination complications and reactions were assessed at different stages, monitoring the state of health and assessing the dynamics of the post-vaccination immune response.Results. A study conducted after 6 weeks showed the high immunological efficacy of the Gam-Covid-Vac vaccine; 100% of those vaccinated with one or two components of the vaccine had class G antibodies to SARS-CoV-2. Vaccination did not cause severe reactions during the observation period; among the side effects, general complaints and local pains at the injection site prevailed, which were of a short-term nature and did not have a significant impact on the health status and habitual rhythm of life of the participants. The resistance of those vaccinated to a new coronavirus infection decreased over time and amounted to 97.1% three months after vaccination and 95.6% after 6 months. COVID-19 disease in vaccinated employees (7.4% of cases of the number of vaccinated) was of moderate severity, did not lead to the development of pneumonia and respiratory failure, and did not require hospitalization.Conclusions. The results obtained allow us to conclude that the effectiveness of vaccination against COVID-19 is quite high. Revaccination is well tolerated clinically and «amplifies» the immune response when exposed to SARS-CoV-2. Immunization of employees of medical organizations is necessary, because. this focus group is the most epidemiologically potentially dangerous in terms of the spread of infection.","PeriodicalId":11736,"journal":{"name":"Epidemiology and Vaccinal Prevention","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epidemiology and Vaccinal Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31631/2073-3046-2023-22-2-86-94","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Relevance. In the 21st century, humanity is faced with a pandemic unprecedented in recent history, which brought with it huge losses. All the efforts of world science are aimed at ensuring that the new coronavirus infection becomes vaccine-controlled. The Ministry of Health of Russia included vaccination against COVID-19 in the national calendar of preventive vaccinations. The most vulnerable and significant in the epidemiological chain are representatives of socially active, intensively communicating professions, including medical workers.Aims. The aim of the study was to assess the degree of severity of the post-vaccination immune response in employees of a medical organization vaccinated with the Gam-COVID-Vac preparation, who had not been ill and did not have antibodies before vaccination.Materials & Methods. The post-vaccination immunity of 80 vaccinated employees was assessed 42–62 days after the start of vaccination and 6 months later; assessment of the safety of vaccination with the Gam-Kovid-Vak vector vaccine; selection of optimal screening tests for laboratory examination of persons before the planned vaccination. The results of the PCR test for the detection of SARS-CoV-2 RNA (at the post-vaccination stage four times with an interval of 7 days) and the determination of M and G immunoglobulins to SARS-CoV-2 by the ELISA method were analyzed, postvaccination complications and reactions were assessed at different stages, monitoring the state of health and assessing the dynamics of the post-vaccination immune response.Results. A study conducted after 6 weeks showed the high immunological efficacy of the Gam-Covid-Vac vaccine; 100% of those vaccinated with one or two components of the vaccine had class G antibodies to SARS-CoV-2. Vaccination did not cause severe reactions during the observation period; among the side effects, general complaints and local pains at the injection site prevailed, which were of a short-term nature and did not have a significant impact on the health status and habitual rhythm of life of the participants. The resistance of those vaccinated to a new coronavirus infection decreased over time and amounted to 97.1% three months after vaccination and 95.6% after 6 months. COVID-19 disease in vaccinated employees (7.4% of cases of the number of vaccinated) was of moderate severity, did not lead to the development of pneumonia and respiratory failure, and did not require hospitalization.Conclusions. The results obtained allow us to conclude that the effectiveness of vaccination against COVID-19 is quite high. Revaccination is well tolerated clinically and «amplifies» the immune response when exposed to SARS-CoV-2. Immunization of employees of medical organizations is necessary, because. this focus group is the most epidemiologically potentially dangerous in terms of the spread of infection.
某医药机构职工新冠肺炎疫苗接种结果分析
的相关性。进入21世纪,人类正面临一场近代史上前所未有的大流行,疫情给人类带来巨大损失。世界科学界的所有努力都是为了确保新型冠状病毒感染得到疫苗控制。俄罗斯卫生部将COVID-19疫苗接种列入国家预防性疫苗接种日程。流行病学链中最脆弱和最重要的群体是社会活跃、交流频繁的职业代表,包括医务工作者。该研究的目的是评估接种了Gam-COVID-Vac制剂的医疗机构员工接种疫苗后免疫反应的严重程度,这些员工在接种疫苗前没有生病,也没有抗体。材料与方法。在接种疫苗后42 ~ 62天和6个月对80名接种疫苗的员工进行免疫后免疫评估;Gam-Kovid-Vak载体疫苗接种安全性评价;为计划接种疫苗前的人员实验室检查选择最佳筛选试验。分析接种后4次SARS-CoV-2 RNA PCR检测结果(接种后4次,间隔7 d)和ELISA法测定对SARS-CoV-2的M、G免疫球蛋白,评估接种后不同阶段的并发症和反应,监测健康状况,评估接种后免疫反应动态。6周后进行的一项研究显示,Gam-Covid-Vac疫苗具有很高的免疫功效;接种一种或两种疫苗成分的人100%具有SARS-CoV-2的G类抗体。观察期间未发生严重反应;副作用中以全身不适和注射部位局部疼痛为主,均为短期,对受试者的健康状况和习惯生活节奏无显著影响。接种疫苗的人对新型冠状病毒感染的抵抗力随着时间的推移而下降,接种后3个月为97.1%,6个月后为95.6%。接种疫苗的员工(占接种人数的7.4%)的COVID-19疾病严重程度中等,未导致肺炎和呼吸衰竭的发展,不需要住院治疗。获得的结果使我们得出结论,接种COVID-19疫苗的有效性相当高。再次接种疫苗在临床上具有良好的耐受性,并且在暴露于SARS-CoV-2时可以“放大”免疫反应。医疗机构员工的免疫接种是必要的,因为。就感染传播而言,这一焦点群体在流行病学上是最具潜在危险的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信